Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2005
11/10/2005US20050250720 Novel compound
11/10/2005US20050250719 Inhibition of protein kinase c alpha for treatment of diabetes mellitus and cardiovascular diseases
11/10/2005US20050250716 Immunostimulatory oligodeoxynucleotides
11/10/2005US20050250707 HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
11/10/2005US20050250706 Processes for the preparation of alpha polymorph of perindopril erbumine
11/10/2005US20050250705 Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
11/10/2005US20050250704 Powder comprising new compositions of oligosaccharides and methods for their preparation
11/10/2005US20050250703 Antioxidant constituents
11/10/2005US20050250702 Controlling availability or activity of proteins by use of protease inhibitors or receptor fragments
11/10/2005US20050250701 Method of treating the syndrome of coronary heart disease risk factors in humans
11/10/2005US20050250700 KDR and VEGF/KDR binding peptides
11/10/2005US20050250699 Antimicrobial polypeptides
11/10/2005US20050250698 Method for obtaining a TGF-beta enriched protein fraction in activated form, protein fraction and therapeutic applications
11/10/2005US20050250697 Method for obtaining a TGF-beta enriched protein fraction in activated form, protein fraction and therapeutic applications
11/10/2005US20050250696 Truncated soluble tumor necrosis factor type-I and type-II receptors
11/10/2005US20050250695 Combination PDGF, KGF, IGF, and IGFBP for wound healing
11/10/2005US20050250694 Diabetes, chronic inflammation, brain edema, edema, arthritis, uvietis, ascites, macular edema, cancer, hyperglycemia, kidney inflammation and other kidney disorders; retina
11/10/2005US20050250693 Metalloproteinase inhibitors
11/10/2005US20050250692 transforming growth factor and insulin like growth factor binding protein 3 as ligands that engage low density lipoprotein receptor-related protein
11/10/2005US20050250691 Stimulation of insulin production by injecting a human recombinant GAD65 protein and adjuvant; immunosuppression towards glutamic acid decarboxylase; gene therapy
11/10/2005US20050250690 Leptin peptide antagonists
11/10/2005US20050250689 Antagonists for human prolactin
11/10/2005US20050250688 Adding to blood a deactivated, genetic engineered mutein; anticoagulants
11/10/2005US20050250687 Anti-tumor activity of Ea-4-peptide of pro-IGF-I
11/10/2005US20050250686 Angiogenesis using hepatocyte growth factor
11/10/2005US20050250685 Peptides with wound healing activity
11/10/2005US20050250684 Method for reducing morbidity and mortality in critically ill patients
11/10/2005US20050250682 Xerostomia, or platelet aggregation disorder
11/10/2005US20050250681 Treatment of ocular diseases and disorders using lantibiotic compositions
11/10/2005US20050250680 Treating leukemia by administering a cross-linked polypeptide antiapoptosis agent having at least two modified amino acids ("hydrocarbon stapling"); crosslinking increases cell permeability
11/10/2005US20050250679 Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use
11/10/2005US20050250678 polypeptide (interferon, colony stimulating factor, human growth hormone) having an O-linked glycosylation site that does not exist in a wild type polypeptide; glycoconjugates in which a species such as a water-soluble polymer, a therapeutic agent or a biomolecule is covalently linked through the site
11/10/2005US20050250677 Glycopeptide antibiotic derivatives
11/10/2005US20050250676 Method of activating insulin receptor substrate-2 to stimulate insulin production
11/10/2005US20050250675 Ketospirocyclopropaneindene compounds; anticarcinogenic agents
11/10/2005US20050250674 Nutritional and food supplement preparation comprising creatine and orotic acid complexes, derivatives and analogs
11/10/2005US20050250673 Neurodegenerative disease treatment
11/10/2005US20050250206 Development of DNA probes and immunological reagents specific for cell surface-expressed molecules and transformation-associated genes
11/10/2005US20050250203 Embryonic or stem-like cell lines produced by cross species nuclear transplantation
11/10/2005US20050250196 Recombinant microorganisms expressing an oligosaccharide receptor mimic
11/10/2005US20050250184 Peptide hormones zalpha48 and zsig97
11/10/2005US20050250183 In vivo incorporation of unnatural amino acids
11/10/2005US20050250180 Secreted protein and polynucleotides encoding them
11/10/2005US20050250167 Purified pkb ser 473 kinase and uses thereof
11/10/2005US20050250153 Novel fetal genes
11/10/2005US20050250150 outer membrane proteins (OMPs) that, alone or in combination, are capable of inducing protective immunity against Lawsonia intracellularis bacteria
11/10/2005US20050250144 Novel genes encoding protein kinase/protein phosphatase
11/10/2005US20050250131 Methods for obtaining thermostable enzymes, DNA polymerase I variants from Thermus aquaticus having new catalytic activities, methods for obtaining the same, and applications of the same
11/10/2005US20050250114 Method for decreasing the number of free virus particles within the bodily fluids of a virally-infected mammal
11/10/2005US20050250113 Mammalian magnesium/manganese sensing G protein coupled receptor
11/10/2005US20050250110 PNA conjugate for treating chronic myeloid leukemia (CML)
11/10/2005US20050249828 Canola protein isolate compositions
11/10/2005US20050249815 Process for producing a plasma protein-containing medicament
11/10/2005US20050249797 Self forming, thermodynamically stable liposomes and their applications
11/10/2005US20050249786 Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
11/10/2005US20050249783 Method of improving absorption of vitamin e by a pet animal
11/10/2005US20050249777 Implantable medical devices incorporating plasma polymerized film layers and charged amino acids
11/10/2005US20050249760 Human body affinitive lubricating protective and repair gel
11/10/2005US20050249756 Use of human prostate cell lines in cancer treatment
11/10/2005US20050249746 useful in inducing a protective immune response against NTHi in an immunized human
11/10/2005US20050249743 Isolated peptides which bind to HLA-A24 molecules and uses thereof
11/10/2005US20050249742 Compositions and methods for modulating a cytotoxic T lymphocyte immune response
11/10/2005US20050249741 Novel Semaphorin gene: Semaphorin W
11/10/2005US20050249740 with cyclodextrins, polyoxyethylene glycol; anticancer agents
11/10/2005US20050249738 Immunotoxins directed against malignant cells
11/10/2005US20050249737 Dendritic cell potentiation
11/10/2005US20050249734 Cortistatin: neuropeptides, compositions and methods
11/10/2005US20050249727 Prevention and treatment of amyloidogenic disease
11/10/2005US20050249726 Useful as therapeutic agent and diagnostic tool for brain tumors which strongly express antigen that is recognized by this antibody
11/10/2005US20050249725 Improving cognitive function of individuals with beta amyloid disfunction utilizing beta amyloid specific immunoglobulin; immunotherapeutics
11/10/2005US20050249721 Compositions and methods for targeted biological delivery of molecular carriers
11/10/2005US20050249720 Cosmetic skin formulation
11/10/2005US20050249719 Using glutenase mixture for treatment and prevention of celiac sprue and/or dermatitis herpetiformis
11/10/2005US20050249718 Compositions and methods for treating disorders associated with abnormal phosphate metabolism
11/10/2005US20050249717 Use of hyaluronidase for preventing and treating cardio vascular diseases
11/10/2005US20050249715 Lactoperoxidase; antiinflammatory; thrombocytosis, myeloma, Castleman syndrome, cardiac myxoma, glomerulonephritis, rheumatoid arthritis, sepsis, influenza-virus infectious disease
11/10/2005US20050249714 Method of using secretin and compositions made therefrom for the treatment of autism and other neurological, behavioral and immunological disorders
11/10/2005US20050249713 Dietary supplement energy-providing to skeletal muscles and protecting the cardiovascular tract
11/10/2005US20050249712 Methods for use of TSLP and agonists and antagonists thereof
11/10/2005US20050249710 biodegradable drug delivery system containing an immunosuppressive agent and a bioerodible polymer comprising hydroxyaliphatic carboxylic acids, and polysaccharides
11/10/2005US20050249709 Bone substitute
11/10/2005US20050249706 Using transgenic and attenuated salmonella comprising tumor modulatory proteins and pharmceutical conjugate to treat cell proliferative disorders; targeted tissue therapy
11/10/2005US20050249705 Inactivated herpes simplex virus glycoprotein for treating metastasis; ultraviolet radiation and heating; highly safe
11/10/2005US20050249704 Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
11/10/2005US20050249703 A polynucleotide encoding a carboxy-truncated interferon gamma (IFNG) polypeptide mutant exhibiting IFNG receptor binding activity having the amino acid sequence, SEQ ID NO:12, or 1-10 residue modifications; antitumor, -carcinogenic agent; viricides; interstitial lung diseases; autoimmune diseases
11/10/2005US20050249702 (1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease
11/10/2005US20050249701 Il-7 Drug substance, composition, preparation and uses
11/10/2005US20050249700 Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
11/10/2005US20050249699 Immunodynamic complexes and methods for using and preparing such complexes
11/10/2005US20050249698 Synergistic effect of the osteogenic growth peptide and the granulocyte clony stimulating factor on haematogenesis
11/10/2005US20050249674 aerosol composition comprising a propellant and a first particulate material comprising particles having a median aerodynamic diameter with the range 0.05 to 11 mu m, such as a medicament suitable for pulmonary inhalation, and a second particulate material comprising particles having a median volume
11/10/2005US20050249670 Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
11/10/2005DE202004020676U1 Storage-stable liquid erythropoietin formulation, for treatment of renal insufficiency, comprises specified amino acids but no preservatives, urea or albumen and is not a reconstituted lyophilizate
11/10/2005DE102004017982A1 Composition, useful or cosmetic or medicinal purpose e.g. in the form of mask, comprises collagen (e.g. fish collagen) and carbohydrates (e.g. carboxymethyl cellulose)
11/10/2005DE102004017376A1 Pretreatment composition, useful for epilation, comprises a univalent 2-6C alcohol (e.g. ethanol), film builders (e.g. alkyl lactate) and analgesic (e.g. N-acetyl-tyrosyl-arginyl-hexadecyl-ester) and/or antiirritants
11/10/2005CA2607113A1 Interleukin-1 receptor antagonists, compositions, and methods of treatment
11/10/2005CA2582265A1 Buccal, polar and non-polar sprays containing propofol
11/10/2005CA2564968A1 Modulation of cartilage homeostasis
11/10/2005CA2564613A1 Pseudopeptides growth hormone secretagogues
11/10/2005CA2564521A1 Epitopes related to coeliac disease
1 ... 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 ... 3163